Resverlogix chooses lead molecule for man trial

By Lisa Kerner

Charlotte, N.C., Sept. 11 - Resverlogix Corp. said it has selected lead molecules for the first administration in man studies, a major step in the company's development of its NexVas PR program.

"We expect that by as early as the first-quarter 2007 the study will have shown that the successful results from our animal models are representative for humans helping us to predict the ApoA-I (core protein in good cholesterol, or HDL) raising properties in humans," president and chief executive officer Don McCaffrey said in a news release.

Resverlogix is a biotechnology company located in Calgary, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.